Stem Cell Therapy for stroke rehabilitation in Turkey – Istanbul
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Clinical guide to MSC therapy after stroke in Turkey: evidence limits, rehabilitation priorities, candidacy, exclusions and accessible Istanbul travel planning.
Can stem cell therapy help stroke recovery?
Mesenchymal stem cell therapy is not an approved treatment for ischaemic or haemorrhagic stroke. Phase 2 trials have reported acceptable safety, but larger controlled studies have not demonstrated a consistent, clinically meaningful improvement in modified Rankin Scale outcomes at 3 or 6 months. Time-sensitive care in the acute phase (thrombolysis, thrombectomy where eligible) and structured neurorehabilitation afterwards remain the evidence-based path.
Key facts
- Approval status
- Not approved for stroke
- Evidence
- Phase 2 safety; efficacy on mRS not consistent
- Standard care
- Acute reperfusion, then structured neurorehabilitation
What we know
- Intravenous and intra-arterial MSC studies in ischaemic stroke have met short-term safety endpoints.
What remains uncertain
- Whether any timing, route or dose reliably improves 90-day functional outcomes.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Stroke (chronic and subacute)
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Several randomised trials and meta-analyses; effects on disability remain uncertain
- Main outcomes studied
- Modified Rankin Scale
- NIHSS
- Motor function (Fugl-Meyer)
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Stroke (chronic and subacute) — PubMed
- Randomised controlled trials — Stroke (chronic and subacute) — PubMed
- Registered MSC trials — Stroke (chronic and subacute) — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Records before recommendations
A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.
No outcome guarantee
The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.
Plan for continuity
Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.
A decision guide for patients comparing care
This page is for patients and families researching regenerative options for stroke rehabilitation and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.
Before considering stem cell therapy for stroke rehabilitation
The key question: What phase of recovery is the patient in, what deficits remain and which goals can be measured alongside—not instead of—rehabilitation?
Evidence status
Cell-based approaches after stroke remain investigational. They do not replace time-critical acute stroke care or structured multidisciplinary rehabilitation.
Standard care first
Neurology review, secondary prevention and physiotherapy, occupational, speech and swallowing rehabilitation remain essential.
What the review checks
Stroke type and date, imaging, deficits, swallowing, seizures, cognition, antithrombotic treatment, rehabilitation progress and travel fitness.
When we redirect
New neurological symptoms, unstable blood pressure, aspiration risk, active clotting or bleeding concerns, or inability to travel safely requires local care.
Planning treatment in Istanbul
Arrange wheelchair-accessible travel, caregiver support, medication continuity, pressure-area care and a rehabilitation handover for home.
How are stem cell and exosome approaches discussed for stroke rehabilitation?
Cell-based stroke research explores whether signalling may support the recovery environment after brain injury. It does not replace emergency stroke treatment, secondary prevention or the repetitive task-based work of rehabilitation.
The review should distinguish acute care from chronic recovery and define functional goals such as mobility, communication or participation. Any proposed intervention is considered alongside—not instead of—multidisciplinary rehabilitation.
Who may be considered?
Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.
- A medically stable recovery phase after acute stroke care
- Defined rehabilitation goals and recent neurology or rehabilitation reports
- Safe swallowing, mobility and travel support arrangements
Who may not be suitable?
New neurological symptoms, unstable blood pressure, aspiration risk, active clotting or bleeding concerns, or inability to travel safely requires local care.
Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.
How is a protocol for stroke rehabilitation planned?
Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.
- 1
Records and diagnosis review
Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether stroke rehabilitation is stable enough for elective travel.
- 2
Product and route discussion
If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.
- 3
Individual written plan
Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.
- 4
Discharge and follow-up handover
Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.
What results can realistically be expected?
The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.
- There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
- Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
- The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
- No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.
Why patients consider StemCell Longevita for stroke rehabilitation
Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:
Records are reviewed before a treatment recommendation or travel booking is requested
The medical team can explain why an enquiry may be declined or redirected
The proposed product, source, testing, route and traceability documents are identified in writing
Investigational options are distinguished from established treatment and medication is not stopped without the home clinician
The quotation separates clinical services, travel support, exclusions and potential extra costs
Discharge documents and a follow-up pathway are prepared for continuity with the home specialist
International patient journey for stroke rehabilitation
Arrange wheelchair-accessible travel, caregiver support, medication continuity, pressure-area care and a rehabilitation handover for home.
- 1
Private record review
Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.
- 2
Written planning before booking
Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.
- 3
Assessment in Istanbul
Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.
- 4
Discharge and return home
Travel timing and support are adapted to stroke rehabilitation. Warning signs, medication continuity and relevant documents are reviewed before departure.
- 5
Remote follow-up
Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.
How much does treatment for stroke rehabilitation cost in Turkey?
A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.
- Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
- Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
- Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.
Frequently asked questions about stroke rehabilitation
Related clinical questions
Where this page sits in the wider picture.